

**May 25, 2026**

To

**BSE Limited,**

Listing Department, P J Towers,  
Dalal Street,  
Mumbai – 400 001.

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Scrip Code: 540679**

**Trading Symbol: HALEOSLABS**

**SUB: COMMUNICATION TO SHAREHOLDERS (Saksham Niveshak).**

Ref: Our earlier communication dated :-

(i) 01.06.2022, (ii) 22.02.2023, (iii) 27.02.2024, (iv) 13.07.2024 & (v) 01.07.2025.

Dear Sir/Madam,

In continuation to our aforesaid earlier intimations, the Company has sent **6<sup>th</sup> Reminder** on May 25, 2026, to those shareholders whose KYC are not yet updated, through its Registrar and Share Transfer Agent, M/s. Aarthi Consultants Pvt Ltd, announcing the launch of the Second 100 Days Campaign titled "Saksham Niveshak" from April 1, 2026 to July 9, 2026, requesting them to update / submit their Bank, KYC and Nomination details.

**Formats are available on the website of the Company @ [www.haleoslabs.com](http://www.haleoslabs.com)**



Further, pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Fifth Amendment) Regulations, 2025, all future dividend payments shall be made only through electronic modes approved by the Reserve Bank of India (RBI). Accordingly, the Company shall discontinue payment of dividend(s) through physical modes, including Dividend Warrants. Shareholders who have not yet registered or updated their valid bank account details with the Company / Depository Participant(s) will not be able to receive dividend payments until such details are duly registered or updated.

Kindly take the same on record and suitably disseminate it to all concerned.

**For Haleos Labs Limited**

(Formerly known as "SMS Lifesciences India Limited")

  
**Trupti Ranjan Mohanty**

Company Secretary



Enclosed:

- 1) Email reminder sent to shareholders (Dt: 25.05.2026)
- 2) Newspaper publication (Dt: 25.05.2026)

**Haleos Labs Limited**

(Formerly SMS Lifesciences India Limited)

**Registered & Corporate Office:** Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad – 500 096, Telangana, India.

Tel: +91-40-6628 8888 | CIN - L74930TG2006PLC050223 | info@haleoslabs.com | www.haleoslabs.com



# Haleos Labs Limited

[Formerly known as SMS Lifesciences India Limited]  
CIN: L74930TG2006PLC050223

Registered office: Plot. No. 19-III, Road No.71, Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills, Hyderabad-500 096

Phone. No: 040-66288888 Fax: 040-23551401

website: [www.haleoslabs.com](http://www.haleoslabs.com) | email: [cs@haleoslabs.com](mailto:cs@haleoslabs.com)

Reminder no. VI

Ref: SLS/ACPL/2026/505001

Date: 25-05-2026

~~\*\*\*\*\*~~

~~\*\*\*\*\*~~

~~\*\*\*\*\*~~

~~\*\*\*\*\*~~

~~\*\*\*\*\*~~

SPECIMEN

**Sub: Reminder to Shareholders regarding Updation of PAN, KYC and Bank Details pursuant to the Second 100-Day Special Outreach Initiative titled "Saksham Niveshak"**

Ref - Our earlier communications dated 01/06/2022, 22/02/2023, 27/02/2024, 13/07/2024 & 01.07.2025.

It is to bring to your notice that pursuant to Investor Education and Protection Fund Authority (IEPFA) and Ministry of Corporate Affairs (MCA) communication dated 27<sup>th</sup> March 2026, your Company is pleased to inform you of the commencement of second 100-days special outreach initiative titled "**Saksham Niveshak**" starting from **1<sup>st</sup> April, 2026 to 9<sup>th</sup> July, 2026** also read along with SEBI vide its circular dated 3<sup>rd</sup> November, 2021 (subsequently amended by circulars dated 14<sup>th</sup> December, 2021, 16<sup>th</sup> March, 2023 and 17<sup>th</sup> November, 2023 read with SEBI Master Circulars dated 7<sup>th</sup> May, 2024 and 10<sup>th</sup> June, 2024), wherein the shareholders are required to update their KYC details, bank mandates and contact information to facilitate direct payment of unpaid/unclaimed dividends to the rightful shareholders and to prevent transfer of unpaid or unclaimed dividends/shares to Investor Education and Protection Fund ("IEPF"),

This campaign is being undertaken to facilitate shareholders in updating Know Your Customer (KYC) details including:

- Bank account mandates
- Nominee Registration
- Contact information (email, mobile number, address)

This campaign is also being undertaken to facilitate the shareholders to claim their Unpaid / unclaimed Dividends for any financial year in order to prevent their dividend amount and shares being transferred to IEPFA.

Further we wish to inform that pursuant to the Amendment to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the provisions of Regulation 12 read with Schedule I have been amended by omitting the provisions related to issue of "**Dividend Warrants**" with effect from 18<sup>th</sup> November, 2025.

Conti...

Hence, all future dividend payments shall be made only through electronic modes of payment approved by the Reserve Bank of India (RBI). The Company will not be paying dividend(s) through physical mode i.e., 'Dividend Warrants'. Shareholders who have not registered or updated their valid bank account details will not be able to receive dividends until such details are duly registered / updated.

In this regard, shareholders are requested to:

- a) Ensure that bank account details are correctly registered / updated with the Registrar and Share Transfer Agent (RTA) to enable the electronic credit of dividend.
- b) Update the email address and contact number for timely receipt of dividend intimations and other communications.

Shareholders holding shares in physical mode are requested to convert their shares to demat mode at the earliest possible opportunity as it will be beneficial for market liquidity.

Shareholders who have not claimed their dividend or have not completed KYC updation are requested to furnish Information / documents, as per the table below, to the RTA of the Company i.e., M/s Aarthi Consultants Private Limited, # 1-2-285, St No: 7, Domalguda, Hyderabad-500029, Telangana, India (email id: info@arthiconsultants.com).

S. No.	Purpose	Form
1	Request for registering PAN, KYC details or changes/updation thereof	Form ISR-1
2.	Confirmation of Signature of securities holder by the Banker	Form ISR-2
3.	Registration of Nomination (Nomination Form) *	Form SH-13
4.	Declaration Form for Opting-out of Nomination*	Form ISR-3
5.	Cancellation or Variation of Nomination	Form SH-14

\*In case you are opting out for giving nomination, submit Form ISR-3 and Form SH-13 need not besubmitted.

The aforesaid forms can be downloaded from the websites of the Company and the RTA at [www.haleoslabs.com/shareholding-information/](http://www.haleoslabs.com/shareholding-information/) & [www.aarthiconsultants.com](http://www.aarthiconsultants.com)

Shareholders are requested to take prompt action during the campaign period to safeguard their entitlements and ensure compliance with applicable statutory requirements.

**For Haleos Labs Limited**  
(Formerly known as "SMS Lifesciences India Limited")  
Sd/-  
**Trupti Ranjan Mohanty**  
Company Secretary



**Notice**

NOTICE is hereby given that the following share certificates of VEDANTA LIMITED standing in the names of K. BABU SAMUEL AND JACOB SAMUEL has been lost/misplaced and the undersigned has applied to the company for issue duplicate share certificates for the said shares.

Folio No.	Name of the Shareholder	Share Certificate nos.	Distinctive Nos.	No of shares
K006074	K BABU SAMUEL JT. JACOB SAMUEL	820074	392315201 392316240	1040
	K BABU SAMUEL JT. JACOB SAMUEL	820074	785935401 785936440	1040

Any person(s) who has any claim(s) with the company in respect of the said share securities should write to our registrar, Kfin Technologies Limited, Selenium Tower B, Plot No. 31-32, Gachibowli, Financial District, Hyderabad-500032 within 15 days from this date else the company will proceed to issue duplicate certificates.

K. BABU SAMUEL  
AND/OR HOUSE, VELIYATHUNDU ROAD,  
SETTLEMENTS H S SCHOOL  
ALUVA 2 UNION CRISTIAN COLLEGE S.O  
ERNAKULAM, 683102

Date : 25.05.2026  
Place : ERNAKULAM

**Chola**  
Financial Holdings

**Cholamandalam Financial Holdings Limited**  
Regd. Office: 'Dare House', No. 234, N.S.C. Bose Road, Chennai - 600 001.  
Tel: 044-25306486; Fax: 044-42110404  
E-mail ID: investorservices@cchl.murugappa.com; Website: www.cholafhl.com  
CIN:L65100TN1949PLC002905

**NOTICE TO MEMBERS**

Notice is hereby given pursuant to section 124(6) of the Companies Act, 2013 (the Act) and the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs (MCA).

As per the above provisions, all shares in respect of which dividends have not been paid or claimed for seven consecutive years or more are required to be transferred to the demat account of the Investor Education and Protection Fund (IEPF) Authority. In respect of the Final Dividend declared in the financial year 2018-19, the due date for transfer of the shares is **7<sup>th</sup> September, 2026**. Individual communication is being sent to the concerned shareholders whose shares are liable to be transferred to IEPF Authority at the latest available address advising them to claim their dividends. The concerned shareholders are requested to make an application along with the requisite documents to the Company / Kfin Technologies Limited (RTA).

In case the Company / RTA does not receive the requisite documents by **15<sup>th</sup> August, 2026**, the Company shall, in compliance with the requirements of the said Rules, transfer the dividend/shares to the IEPF as per procedure stipulated in Rules, without any further notice.

Details of shareholders including the name, folio number/DP ID/client ID and equity shares due for transfer to IEPF Authority are being uploaded on the Company's website at <http://www.cholafhl.com> for verification by concerned shareholders.

Shareholders may note that both unclaimed dividend and the shares transferred to the IEPF including all benefits accruing on such shares, if any, can be claimed by them from the IEPF Authority after following the due procedure prescribed in the Rules.

For further information / clarification, concerned shareholders may contact the Company or the RTA at the following address:

<b>Cholamandalam Financial Holdings Limited</b> Regd. Off: 'Dare House', No.234, N.S.C. Bose Road, Chennai - 600 001. Tel: 044-25306486; Fax: 044-42110404 Email: investorservices@cchl.murugappa.com Website: www.cholafhl.com	<b>Kfin Technologies Limited</b> Kany Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500 032 Toll Free No.: 1800 309 4001 Fax No: 040-2342 0814 Email: einward.ris@kfintech.com Website: www.kfintech.com or ris.kfintech.com
---	---

Kind Attention: Shareholders holding securities in physical mode are requested to have their holdings dematerialised at the earliest. Further, as per SEBI mandate updation of KYC details with RTA and linking of PAN with Aadhar shall be completed at the earliest.

For **Cholamandalam Financial Holdings Limited**  
E. Krithika  
Company Secretary  
Chennai  
May 25, 2026

manipalhospitals  
LIFE'S ON

**Manipal Hospitals Private Limited**

CIN: U85110KA2003PTC033055  
Registered office: THE ANNEXE, #98/2, Rustom Bagh, HAL Airport Road, Bangalore, Karnataka, India, 560017  
Tel: +91 8049360300 | Email id: info@manipalhospitals.com | Website: www.manipalhospitals.com

**Statement of audited standalone and consolidated financial results for the year ended March 31, 2026**

The Board of Directors of the company at the meeting held on May 22, 2026, approved the audited standalone and consolidated financial results of the Company along with auditors' report thereon for the year ended March 31, 2026

The Financial Results along with the Auditor's Report have been hosted on Company's website at <https://www.manipalhospitals.com/financial-reports#quarterly-results> and on the website of BSE Limited at <https://www.bseindia.com/xml-data/corpfiling/Attach-Live/20209ce6-06f0-4b9b-9062-02c44b3713ec.pdf> and can be accessed by scanning the QR code.



For and on behalf of the Board of Directors  
Manipal Hospitals Private Limited

**Dr. H Sudarshan Ballal**  
Chairman  
DIN: 01195055

Location: Bengaluru  
Date: May 22, 2026

Note: The above information is accordance with Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**Haleos Labs Limited**  
[Formerly known as SMS LIFESCIENCES INDIA LIMITED]  
CIN: L74930TG2006PLC050223

Registered office : Plot.No. 19-III, Road No.71, Opp. Bharathi Vidya Bhavan Public School, Jubilee Hills, Hyderabad-500 096. Phone. No : 040-66288888  
Fax : 040-23551401, website: www.smslife.in, email: cs@smslife.in

**NOTICE TO SHAREHOLDERS**  
Second 100 days campaign - "Saksham Niveshak" - for KYC and other related updation and shareholder engagement to prevent transfer of unpaid/unclaimed dividends to Investor Education and Protection Fund ("IEPF")

Notice is hereby given to the shareholders of Haleos Labs Limited ("Company"), pursuant to the communication dated March 27, 2026, received from the Investor Education and Protection Fund Authority ("IEPFA"), that the Company is pleased to announce the launch of the Second 100 Days Campaign titled "Saksham Niveshak" from April 01, 2026 to July 09, 2026.

During this campaign, shareholders who have not claimed their dividends, or have not updated their KYC and nomination details, or are facing any issues relating to unclaimed dividends and shares, may contact the Company's Registrar and Share Transfer Agent ("RTA") - M/s. Aarthi Consultants Private Limited # 1-2-285, Street No. 7, Domalguda, Hyderabad - 500029, Telangana, India Email: info@arthiconsultants.com & Shareholders may also write to the Company at : cs@haleoslabs.com

The shareholders are further informed that this campaign has been re-launched proactively to encourage shareholders to update their KYC details, bank mandates, nomination and contact information, etc., and to claim their unpaid/unclaimed dividends, thereby preventing transfer of shares and dividend amounts to the IEPF Authority.

For **Haleos Labs Limited**  
**Trupti Ranjan Mohanty**  
Company Secretary  
Place : Hyderabad  
Date : 25.05.2026

**TATA**  
**TATA CHEMICALS LIMITED**  
Corporate Identity Number: L24239MH1939PLC002893  
Registered Office: Bombay House, 24 Homi Mody Street, Fort, Mumbai - 400 001  
Tel. No.: +91 22 6665 8282  
Email: investors@tatachemicals.com Website: www.tatachemicals.com

**NOTICE TO SHAREHOLDERS**  
Issued in support of Second 100-day Campaign- "Saksham Niveshak" to Facilitate Payment of Unpaid Dividend and KYC Updates

Pursuant to the letter dated March 27, 2026 issued by the Ministry of Corporate Affairs (MCA), Investor Education and Protection Fund Authority (IEPFA) has initiated a Second 100 Days Campaign - "Saksham Niveshak" from April 1, 2026 to July 9, 2026 to reach out to shareholders whose dividend(s) has remained unpaid/unclaimed and whose KYC details have not been updated.

In line with this initiative, the shareholders of Tata Chemicals Limited who have unpaid/unclaimed dividend(s) with the Company or whose KYC details, (viz., PAN, Bank account details, contact details, choice of nomination, specimen signature), have not been updated are requested to follow the below procedure:

- For shares held in physical form - Download the forms for KYC updation from <https://web.in.mpms.mufg.com/KYC-downloads.html> and submit the duly filled and signed forms along with KYC documents to Company's Registrar and Transfer Agent (RTA) i.e. **MUFG Intime India Private Limited** at their address: C-101, 1<sup>st</sup> Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai - 400 083, Telephone No +91 81081 18484.
- For shares held in dematerialised form - Update the KYC details with their respective Depository Participant (DP) and submit the self-attested copy of the updated Client Master List to Company's RTA.

The unclaimed/unpaid dividend(s) will be credited to the shareholder's bank account only after the KYC is updated. Details of unclaimed dividend(s) are available on the website of the Company at <https://www.tatachemicals.com/investor/investor-resources/unclaimed-dividends>. Shareholders may also reach out to the Company at [investors@tatachemicals.com](mailto:investors@tatachemicals.com) or raise a service request on [https://web.in.mpms.mufg.com/helpdesk/Service\\_Request.html](https://web.in.mpms.mufg.com/helpdesk/Service_Request.html) for any assistance in this regard.

For **Tata Chemicals Limited**  
Sd/-  
**Jeraz E. Mahesh**  
Company Secretary  
(FCS 7008)  
Place: Mumbai  
Date: May 22, 2026

**PONNI SUGARS (ERODE) LIMITED**  
CIN:L15422TN1996PLC037200

Regd. Office: 'ESVNH House', 13 Rajiv Gandhi Sala (OMR), Perungudi, Chennai 600 096  
Phone: 044-24961920, 24960156, Email: admin@ponnisugars.com  
Investor Grievance ID: investor@ponnisugars.com Website: www.ponnisugars.com

ISO 9001/14001 CERTIFIED

**NOTICE FOR THE ATTENTION OF SHAREHOLDERS OF THE COMPANY REGARDING THE 30th AGM**

**1. AGM Notice**  
Notice is hereby given that the 30th Annual General Meeting (AGM) of the Company will be held thro' Video Conference (VC) / Other Audio Visual Means (OAVM) on **Wednesday, the 24th June 2026 at 11.00 AM** in compliance with the provisions of the Companies Act, 2013, General Circular No.03/2025 dated 22.09.2025 issued by MCA in continuation of its earlier circulars, to transact the business set out in the Notice convening the AGM.

**2. Service of documents**  
In deference to the above and SEBI Regulations, electronic copy of the Annual Report for FY 2025-26 comprising the Notice of the 30th AGM, Financial Statements, Board's Report, Auditors' Report and other documents required to be attached thereto is being sent to all the members whose email addresses are registered with the Depository Participants (DPs) / Registrar and Transfer Agent (RTA). Letter providing weblink and exact path of annual report is being sent where e-mail id's are not registered with us. These documents will also be made available on the Company's website ([www.ponnisugars.com](http://www.ponnisugars.com)) and on the websites of the Stock Exchanges i.e. BSE Ltd ([www.bseindia.com](http://www.bseindia.com)) and National Stock Exchange of India Ltd ([www.nseindia.com](http://www.nseindia.com)).

**3. Manner of registering / updating email addresses**  
Members are advised to register / update their email address and mobile number immediately, in case they have not done so earlier:

- In case of shares held in demat mode, with their respective Depository Participants.
- In case of shares held in physical mode, by accessing the link <https://investor.cameoindia.com> or by email to the RTA at [investor@cameoindia.com](mailto:investor@cameoindia.com) with details of Folio number and attaching a self-attested copy of PAN card.
- After due verification, the Company / RTA will send login credentials for attending the AGM and voting to the registered email address.
- Any person who becomes a member of the company after despatch of the AGM Notice and holding shares as on the cut-off date may obtain the user Id and password in the manner provided in the AGM Notice.

**4. e-Voting**  
The Company is providing e-Voting (remote e-Voting) facility for its members to cast their votes on all resolutions set out in the AGM Notice. Additionally, the Company is providing the facility of voting thro' e-Voting system during the AGM (e-Voting). The cut-off date for remote e-voting / e-voting at AGM is fixed as **Wednesday, the 17th June 2026**. Remote e-voting period for casting of votes is fixed from **Saturday, the 20th June 2026 (10.30 AM) to Tuesday, the 23rd June 2026 (5.00 PM)**. Detailed procedure for joining the AGM and remote e-Voting / e-Voting at AGM is provided in the Notice for 30th AGM.

**5. Dividend**  
The Board of Directors have recommended a dividend of ₹5.00 per equity share for FY 2025-26. The Record Date for dividend is **Friday, the 5th June 2026**. Members are advised to register their Bank account details with their respective DPs (in the case of demat holding) / RTA (in the case of physical holding). As dividend income is taxable in the hands of shareholders, they are advised to register/ furnish details of tax status/ exemption as detailed in the AGM Notice.

**6. Members are advised to refer to the AGM Notice for full content and details. They may write / email to the Company for any clarification.**

Chennai  
23.05.2026

For **Ponni Sugars (Erode) Ltd**  
**R Madhusudhan**  
Company Secretary

(This is only an advertisement for information purpose and not a prospectus announcement. Not for Release or Distribution in the United States.)

**CORRIGENDUM: NOTICE TO INVESTORS**

(Please scan this QR Code to view the RHP)

# Q-LINE BIOTECH LIMITED

## THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NSE ("NSE EMERGE")

CIN: U74120UP2010PLC042528

Our Company was originally incorporated as "POCT Services Private Limited" on November 10, 2010 as a Private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PTC042528. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre. The CIN of the Company is U74120UP2010PLC042528. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "**History and Corporate Structure**" beginning on page 154 of the Red Herring Prospectus.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012  
Tel.: +91 522-2435570, E-mail: [compliance@qlinebiotech.com](mailto:compliance@qlinebiotech.com) Website: [www.qlinebiotech.com](http://www.qlinebiotech.com)  
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer

**OUR PROMOTERS: SAURABH GARG, AMITA GARG, AYUSH GARG, AJAY KUMAR MAHANTY AND ABHAY AGRAWAL**

**THE ISSUE**

INITIAL PUBLIC OFFER OF UPTO 62,53,200 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "QLBL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE (INCLUDING SHARE PREMIUM OF ₹ (●) PER EQUITY SHARE) FOR CASH, AGGREGATING UP TO ₹ (●) LAKHS ("PUBLIC ISSUE") OUT OF WHICH 3,13,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING ₹ (●) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 59,40,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹ (●) LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.81 % AND 25.46 % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**BID/ ISSUE PROGRAM**

**BID/ ISSUE OPENS ON: THURSDAY, MAY 21, 2026**

**BID/ ISSUE CLOSES ON: MONDAY, MAY 25, 2026**

**ATTENTION INVESTORS****CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED MAY 16, 2026**

This is with reference to the Red Herring Prospectus dated May 16, 2026 filed with Registrar of Companies in relation to the Issue, following additions, modifications should be read as under:

- The value of Earnings before interest, tax, depreciation and amortization (EBITDA) for the period ended December 31, 2025 should be read as Rs. 6,422.98 lakhs on page 128 of the chapter titled "**Our Business**"; page 255 of the chapter titled "**Management's Discussion and Analysis of Financial Conditions and Results of Operations**" and page 247 of the chapter titled "**Other Financial Information**".
- The value of Profit after Tax (PAT) for the financial year ended March 31, 2024 should be read as Rs. 3,444.92 lakhs on page 247 of the chapter titled "**Other Financial Information**" and page 260 of the chapter titled "**Management's Discussion and Analysis of Financial Conditions and Results of Operations**".
- The details under heading **Our Competitive Strengths - Track record of healthy financial performance**, the phrase "In Fiscal 2025, 2024 and 2023, our Return on Capital Employed was 17.66%, 19.25%, and 22.14%, respectively and as of March 31, 2025, 2024 and 2023, our Return on Equity was 15.99%, 23.83% and 29.49%, respectively. The Return on Capital Employed and our Return on Equity was 13.32% and 18.46% for the period ended December 31, 2025", should be read as "In Fiscal 2025, 2024 and 2023, our Return on Capital Employed was 17.66%, 19.25%, and 22.14%, respectively and as of March 31, 2025, 2024 and 2023, our Return on Equity (based on Average Shareholder's Equity) was 15.99%, 23.83% and 29.49%, respectively. The Return on Capital Employed and our Return on Equity (based on Average Shareholder's Equity) was 13.32% and 18.46% for the period ended December 31, 2025" on page 131 of the chapter titled "**Our Business**".

The information in this corrigendum supplements and updates the information in the Red Herring Prospectus, as applicable, and the aforementioned changes are to be read in conjunction with the Red Herring Prospectus. Accordingly, appropriate references in the Red Herring Prospectus stand updated pursuant to this corrigendum. Unless further updated, there will be suitable updating in the Prospectus, as and when they are filed with the RoC, the SEBI and the Stock Exchange.

**DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA ("SEBI"):** Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 322 of the Red Herring Prospectus.

**DISCLAIMER CLAUSE OF NSE ("NSE EMERGE") (THE DESIGNATED STOCK EXCHANGE):** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the offer document has been cleared or approved by NSE nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to the full text of the "Disclaimer Clause of the SME Platform of NSE (NSE Emerge)" beginning on page 326 of the Red Herring Prospectus.

**GENERAL RISK:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this Issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the investors is invited to "**Risk Factors**" on page 20 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGERS TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>Hem Securities Limited</b> Address: 904, A Wing, Naman Midtown, Senapati Bagat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India. Tel. No.: +91-22-4906 0000 Email: <a href="mailto:ib@hemsecurities.com">ib@hemsecurities.com</a> Investor Grievance Email: <a href="mailto:redressal@hemsecurities.com">redressal@hemsecurities.com</a> Website: <a href="http://www.hemsecurities.com">www.hemsecurities.com</a> Contact Person: Saurabh Garg SEBI Registration Number: INM000010981 CIN: U67120RJ1995PLC010390	 <b>SHARE INDIA CAPITAL SERVICES PRIVATE LIMITED</b> Address: A 25, Basement, Sector 64, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301 Tel No.: +91 0120-6483000 Email: <a href="mailto:mb@shareindia.com">mb@shareindia.com</a> Website: <a href="http://www.shareindia.com">www.shareindia.com</a> Contact Person: Kunal Bansal SEBI Reg. No.: INM000012537	 <b>PURVA SHAREGISTRY (INDIA) PRIVATE LIMITED</b> Address: 9, Shiv Shakti Industrial Estate, J.R. Boricha Marg Lower Parel (East), Mumbai, Maharashtra, India, 400011 Tel. No.: 91 22-2301-2517 / 8261 Fax No.: +91-022-23012517 Email: <a href="mailto:newissue@purvashare.com">newissue@purvashare.com</a> Website: <a href="http://www.purvashare.com">www.purvashare.com</a> Contact Person: Deepali Dhuri SEBI Registration No.: INR000001112
 <b>Akhand Pratap Singh</b> <b>Q-LINE BIOTECH LIMITED</b> Address: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012 Telephone: +91 522-2435570; Email: <a href="mailto:akhand.singh@qlinebiotech.com">akhand.singh@qlinebiotech.com</a> Website: <a href="http://www.qlinebiotech.com">www.qlinebiotech.com</a> ; CIN: U74120UP2010PLC042528 Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or post-issue related grievances including non-receipt of letters of allotment, non-credit of allotted equity shares in the respective beneficiary account, non-receipt of refund orders or non- receipt of funds by electronic mode, etc. For all issue related queries and for redressal of complaints investors may also write to the BRLMS.		

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus.

Place: Lucknow  
Date: May 23, 2026

**Disclaimer:** Q-Line Biotech Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Red Herring Prospectus dated May 16, 2026 has been filed with the Registrar of Companies, Uttar Pradesh and thereafter with SEBI and the Stock Exchanges. The RHP is available on the website of the SEBI at [www.sebi.gov.in](http://www.sebi.gov.in), website of NSE EMERGE at [www.nseindia.com](http://www.nseindia.com) and is available on the websites of the BRLMS at [www.hemsecurities.com](http://www.hemsecurities.com) and [www.shareindia.com](http://www.shareindia.com). Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled "**Risk Factors**" beginning on page 20 of the Red Herring Prospectus.

On behalf of Board of Directors  
**Q-Line Biotech Limited**  
Sd/-  
**Akhand Pratap Singh**  
Company Secretary and Compliance Officer